News coverage about PTC Therapeutics (NASDAQ:PTCT) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PTC Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.5153364072588 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of PTC Therapeutics (NASDAQ PTCT) opened at $21.49 on Wednesday. The stock has a market capitalization of $891.61, a P/E ratio of -7.44 and a beta of 1.23. PTC Therapeutics has a twelve month low of $8.12 and a twelve month high of $23.71. The company has a current ratio of 3.08, a quick ratio of 2.97 and a debt-to-equity ratio of 0.98.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.01). PTC Therapeutics had a negative return on equity of 75.19% and a negative net margin of 75.64%. equities research analysts predict that PTC Therapeutics will post -2.01 earnings per share for the current fiscal year.
A number of research firms recently commented on PTCT. Zacks Investment Research cut PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Barclays lowered their price target on PTC Therapeutics from $22.00 to $15.00 and set an “equal weight” rating on the stock in a report on Friday, September 29th. ValuEngine raised PTC Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Royal Bank of Canada reissued a “sector perform” rating on shares of PTC Therapeutics in a report on Friday, September 29th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $25.00 price objective on shares of PTC Therapeutics in a report on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $19.14.
In other news, CEO Stuart Walter Peltz sold 2,230 shares of the company’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $18.03, for a total transaction of $40,206.90. Following the sale, the chief executive officer now directly owns 26,646 shares of the company’s stock, valued at approximately $480,427.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 2,719 shares of company stock worth $48,848 over the last ninety days. Insiders own 8.10% of the company’s stock.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.